Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

Based on data from 1.14 million vaccinations which have been administered, scientists from the University of Edinburgh have shown that both the BioNtech/Pfizer and Oxford vaccines are highly effective and that by the fourth week after receiving the initial dose shown to reduce the risk of hospitalisation from COVID-19 by up to 85% and 94%, respectively.

They report that by the fourth week after receiving the initial vaccination, those aged 80 years and over were shown to have an 81% reduction in hospitalisation risk, a combined result for data from those vaccinated with either the Oxford or BionTech/Pfizer vaccines.

Sarah Gilbert, Professor of Vaccinology, said:  

‘The real-world data from Scotland now provides evidence of high effectiveness of both the Oxford/AstraZeneca and BionTech/Pfizer vaccines in preventing hospitalisation in people over the age of 80, after a single dose, supporting our confidence in using this vaccine in adults of all ages.’ 

These data were gathered as part of the EAVE II project, which uses patient data to track the pandemic and the vaccine roll out in real time, with researchers from the Universities of Edinburgh, Strathclyde, Aberdeen, Glasgow and St Andrew’s and Public Health Scotland (PHS) analysing a dataset covering the entire Scottish population of 5.4 million. 

Andrew Pollard, Professor of Paediatric Infection and Immunity, and Chief Investigator on the Oxford vaccine trial, said: 

'We are delighted to see that the real-world evidence reported today from the University of Edinburgh which confirms that both the Oxford-AstraZeneca vaccine and the Pfizer vaccine have a very substantial impact against hospitalisation with COVID19 disease. Vaccines work. We now need to make sure that everyone everywhere is protected'

The news comes as real-world data from vaccination programmes around the world start to become available.

Teresa Lambe, Associate Professor and Jenner Investigator, concludes:

‘When we first started this journey, we could only hope that a year later, real world data would show this level of impact from our vaccine against hospitalisation from severe illness. It is a huge day for us all, especially the team who've worked so hard, and monumental in our battle against coronavirus.’

Similar stories

Oxford Vaccine Group among winners at NHS Parliamentary awards

Researchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.

New book highlights life-saving role vaccines play in prevention of killer diseases

'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.

Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study

Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

First trial participants vaccinated with Oxford COVID-19 variant vaccine

The University of Oxford in partnership with AstraZeneca began vaccinations on 27 June 2021 for a new phase in human trials to test a COVID-19 vaccine ‘AZD2816’ in volunteers against the B.1.351 variant of concern – commonly known as the Beta variant.

Oxford researchers identify levels of antibody protection required to prevent symptomatic COVID-19

Researchers from the University of Oxford have today released their findings about the so-called ‘correlates of protection’ against symptomatic COVID-19; potentially a tool to speed up safe development of new vaccines which may assist regulators in assessing the likely potency of any new COVID-19 vaccine without the need for Phase III efficacy trial data.